Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC), introduce its newest program in human metapneumovirus (hMPV), as well as provide an update on its business outlook for 2020, during Enanta’s presentation at the 38^th Annual J.P. Morgan Healthcare Conference on January 13, 2020 at 2:30 p.m. Pacific Time.

“During 2019, we successfully advanced our lead RSV, NASH and HBV compounds in clinical development, and we look forward to achieving several milestones from these programs in 2020,” commented Jay R. Luly, Ph.D., Enanta President and CEO. “We continue to advance and expand our virology and liver disease assets with the ongoing development of EDP-938 for RSV, the only N-protein inhibitor for RSV in clinical development today -- including plans to initiate Phase 2 pediatric and transplant studies. We are also introducing today our newest program, which is for treatment of hMPV, a pathogen identified in 2001 that causes upper and lower respiratory tract infections in young children and the elderly, as well as COPD, asthma, and immunocompromised patients. Our Phase 1a study of EDP-514, our lead core inhibitor candidate for treatment of chronic HBV, is on track to have topline data from healthy volunteers this quarter. We also expect to have topline data from our INTREPID Phase 2a study of EDP-305 in PBC patients next quarter. In NASH, our Phase 2b study of EDP-305 in biopsy-proven NASH patients, known as ARGON-2, is on track to begin by early next quarter and will include an interim readout at 12-weeks to generate dose information more quickly for potential combinations with other mechanisms in NASH. Additionally, mid-year we are on track to begin Phase 1 with our follow-on FXR agonist candidate EDP-297 for NASH.”

During the presentation, Enanta will discuss development plans for its ongoing clinical programs and its expectations to achieve the following milestones in calendar 2020:

• RSV N-inhibitor EDP-938 and hMPV Inhibitor Leads

­ Goal: Data from RSVP Phase 2b adult outpatient study in 3Q 2020 if enrollment can be completed in one RSV season in northern hemisphere